• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Antibody response after second BNT162b2 dose in allogeneic HSCT recipients.

作者信息

Redjoul Rabah, Le Bouter Anne, Beckerich Florence, Fourati Slim, Maury Sébastien

机构信息

Hopital Henri Mondor, 94000 Créteil, France.

Hopital Henri Mondor, 94000 Créteil, France.

出版信息

Lancet. 2021 Jul 24;398(10297):298-299. doi: 10.1016/S0140-6736(21)01594-4. Epub 2021 Jul 13.

DOI:10.1016/S0140-6736(21)01594-4
PMID:34270933
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8277189/
Abstract
摘要

相似文献

1
Antibody response after second BNT162b2 dose in allogeneic HSCT recipients.异基因造血干细胞移植受者第二次接种BNT162b2后的抗体反应。
Lancet. 2021 Jul 24;398(10297):298-299. doi: 10.1016/S0140-6736(21)01594-4. Epub 2021 Jul 13.
2
Third Early "Booster" Dose Strategy in France of bnt162b2 SARS-CoV-2 Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Enhances Neutralizing Antibody Responses.法国在异基因造血干细胞移植受者中使用 bnt162b2 SARS-CoV-2 疫苗进行第三次早期“加强”剂量的策略增强了中和抗体反应。
Viruses. 2022 Aug 30;14(9):1928. doi: 10.3390/v14091928.
3
SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group.造血干细胞移植受者接种 SARS-CoV-2 疫苗后针对 SARS-CoV-2 的抗体检测：来自西班牙造血干细胞移植和细胞治疗组的前瞻性调查。
Am J Hematol. 2022 Jan 1;97(1):30-42. doi: 10.1002/ajh.26385. Epub 2021 Nov 2.
4
Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier?接受BNT162b2 mRNA疫苗或AZD1222疫苗的健康志愿者中针对SARS-CoV-2的中和抗体反应比较：AZD1222疫苗的第二剂是否应提前接种？
Am J Hematol. 2021 Sep 1;96(9):E321-E324. doi: 10.1002/ajh.26248. Epub 2021 Jun 2.
5
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.立陶宛血液系统恶性肿瘤患者的 BNT162b2 COVID-19 mRNA 疫苗免疫原性和早期临床结局：一项全国前瞻性队列研究。
Lancet Haematol. 2021 Aug;8(8):e583-e592. doi: 10.1016/S2352-3026(21)00169-1. Epub 2021 Jul 2.
6
A cluster of the new SARS-CoV-2 B.1.621 lineage in Italy and sensitivity of the viral isolate to the BNT162b2 vaccine.意大利出现的新型严重急性呼吸综合征冠状病毒2（SARS-CoV-2）B.1.621谱系集群以及病毒分离株对BNT162b2疫苗的敏感性。
J Med Virol. 2021 Dec;93(12):6468-6470. doi: 10.1002/jmv.27247. Epub 2021 Aug 10.
7
[COVID-19 vaccination for allogeneic hematopoietic stem cell recipients].[异基因造血干细胞受体的新冠病毒疫苗接种]
Rinsho Ketsueki. 2022;63(9):1067-1077. doi: 10.11406/rinketsu.63.1067.
8
Three is better than two: humoral response in allogeneic HSCT after the third BNT162b2 SARS-CoV-2 mRNA vaccine.三比二好：第三次接种BNT162b2新冠病毒mRNA疫苗后异基因造血干细胞移植中的体液反应
Eur Rev Med Pharmacol Sci. 2023 Aug;27(15):6914-6916. doi: 10.26355/eurrev_202308_33262.
9
Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in haematopoietic stem cell transplantation recipients.BNT162b2 mRNA COVID-19 疫苗在造血干细胞移植受者中的免疫原性和安全性。
Br J Haematol. 2022 Feb;196(4):884-891. doi: 10.1111/bjh.17918. Epub 2021 Oct 28.
10
Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients.异基因造血细胞移植受者接种2剂和3剂SARS-CoV-2 mRNA疫苗后的抗体反应。
Blood. 2022 Jan 6;139(1):134-137. doi: 10.1182/blood.2021014232.

引用本文的文献

1
Impact of memory T cells on SARS-CoV-2 vaccine response in hematopoietic stem cell transplant.记忆T细胞对造血干细胞移植中SARS-CoV-2疫苗反应的影响。
PLoS One. 2025 Apr 28;20(4):e0320744. doi: 10.1371/journal.pone.0320744. eCollection 2025.
2
Adaptive evolution of SARS-CoV-2 during a persistent infection for 521 days in an immunocompromised patient.一名免疫功能低下患者持续感染521天期间新冠病毒的适应性进化
NPJ Genom Med. 2025 Jan 17;10(1):4. doi: 10.1038/s41525-025-00463-x.
3
Effectiveness and duration of additional immune defense provided by SARS-CoV-2 infection before and after receiving the mRNA COVID-19 vaccine BNT162b2.接种mRNA新冠疫苗BNT162b2前后，SARS-CoV-2感染提供的额外免疫防御的有效性和持续时间。
Vaccine X. 2024 Jun 26;19:100518. doi: 10.1016/j.jvacx.2024.100518. eCollection 2024 Aug.
4
Cellular and humoral immunogenicity against SARS-CoV-2 vaccination or infection is associated with the memory phenotype of T- and B-lymphocytes in adult allogeneic hematopoietic cell transplant recipients.细胞和体液免疫原性针对 SARS-CoV-2 接种或感染与成年异基因造血细胞移植受者的 T 和 B 淋巴细胞记忆表型相关。
Int J Hematol. 2024 Aug;120(2):229-240. doi: 10.1007/s12185-024-03802-3. Epub 2024 Jun 6.
5
SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study.异基因造血细胞移植或嵌合抗原受体 T 细胞治疗后第一年的 SARS-CoV-2 疫苗接种：一项前瞻性、多中心、观察性研究。
Clin Infect Dis. 2024 Aug 16;79(2):542-554. doi: 10.1093/cid/ciae291.
6
Are any specific respiratory viruses more severe than others in recipients of allogeneic stem cell transplantation? A focus on lower respiratory tract disease.同种异体干细胞移植受者中，是否有特定的呼吸道病毒比其他病毒更严重？以下将重点关注下呼吸道疾病。
Bone Marrow Transplant. 2024 Aug;59(8):1118-1126. doi: 10.1038/s41409-024-02304-4. Epub 2024 May 10.
7
Immunologic responses to the third and fourth doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in cell therapy recipients: a systematic review and meta-analysis.细胞治疗受者中对严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）疫苗第三和第四剂的免疫反应：系统评价和荟萃分析。
Virol J. 2024 May 3;21(1):103. doi: 10.1186/s12985-024-02375-1.
8
Spike-Specific Memory B Cell Response in Hematopoietic Cell Transplantation Recipients following Multiple mRNA-1273 Vaccinations: A Longitudinal Observational Study.多次接种mRNA-1273疫苗后造血细胞移植受者的刺突特异性记忆B细胞反应：一项纵向观察研究
Vaccines (Basel). 2024 Mar 29;12(4):368. doi: 10.3390/vaccines12040368.
9
Monitoring Humoral Response Following BNT162b2 mRNA Vaccination against SARS-CoV-2 in Hematopoietic Stem-Cell Transplantation Patients: A Single-Center Prospective Study along with a Brief Review of Current Literature.造血干细胞移植患者接种BNT162b2 mRNA新冠疫苗后的体液免疫反应监测：一项单中心前瞻性研究及当前文献简要综述
Hematol Rep. 2024 Apr 16;16(2):220-233. doi: 10.3390/hematolrep16020022.
10
Immunogenicity and Tolerance of BNT162b2 mRNA Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Patients.BNT162b2 mRNA疫苗在异基因造血干细胞移植患者中的免疫原性和耐受性
Vaccines (Basel). 2024 Feb 8;12(2):174. doi: 10.3390/vaccines12020174.

本文引用的文献

1
COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey.COVID-19 与干细胞移植：来自 EBMT 和 GETH 多中心前瞻性调查的结果。
Leukemia. 2021 Oct;35(10):2885-2894. doi: 10.1038/s41375-021-01302-5. Epub 2021 Jun 2.
2
Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients.实体器官移植受者对两剂严重急性呼吸综合征冠状病毒2信使核糖核酸疫苗系列的抗体反应。
JAMA. 2021 Jun 1;325(21):2204-2206. doi: 10.1001/jama.2021.7489.
3
Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2.先前感染过 SARS-CoV-2 的个体对 BNT162b2 mRNA 疫苗的抗体反应。
Nat Med. 2021 Jun;27(6):981-984. doi: 10.1038/s41591-021-01325-6. Epub 2021 Apr 1.
4
Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study.造血干细胞移植受者 COVID-19 的临床特征和结局：一项观察性队列研究。
Lancet Haematol. 2021 Mar;8(3):e185-e193. doi: 10.1016/S2352-3026(20)30429-4. Epub 2021 Jan 19.